Europe Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID

Europe Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)

Report Code : BMIRE00026300 | Region : Europe | Industry : Pharmaceuticals | Published Date : 26/Sep/2022

The Europe human papillomavirus (HPV) vaccine market is expected to grow from US$ 1,202.66 million in 2022 to US$ 1,598.81 million by 2028; it is estimated to grow at a CAGR of 4.9% from 2022 to 2028.

Human papillomavirus (HPV) is a common sexually transmitted infection and can cause cervical, oropharyngeal cancer, and cancer of the vagina, vulva, penis, or anus. It also causes various diseases, such as anogenital warts and recurrent respiratory papillomatosis. HPVs have also been detected in lichen sclerosus, skin tags, seborrheic keratoses, epidermal cysts, actinic keratoses, and psoriatic plaques. A significant burden of HPV-associated diseases is driving the market. In women, cervical cancer is the fourth most common cancer. In addition, as per the report, titled “Human Papillomavirus and Related Diseases Report-Europe,” in 2020, 8,449 women and 4,327 men had anal cancer in Europe. Such a high incidence rate of HPV-associated infections is favoring the market growth.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the Europe human papillomavirus (HPV) vaccine market . The Europe human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

Europe Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Europe Human Papillomavirus (HPV) Vaccine Market Segmentation

The Europe human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022. Based on dosage, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022. Based on age, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022. Based on application, the Europe human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022. Based on end user, the Europe human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022. Based on country, the Europe human papillomavirus (HPV) vaccine market has been categorized into the UK, Germany, France, Italy, Spain, Russia, Belarus, and the Rest of Europe. Germany would dominate the market in 2022.

2A Pharma ; ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. are among the leading companies in the Europe human papillomavirus (HPV) vaccine market.

At 4.9% CAGR, the Europe Human Papillomavirus (HPV) Vaccine Market is speculated to be worth US$ 1,598.81 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Europe human papillomavirus (HPV) vaccine market was valued at US$ 1,202.66 million in 2022 and is expected to reach US$ 1,598.81 million by 2028, registering an annual growth rate of 4.9% from 2022 to 2028. The growing number of HPV awareness programs and increase in prevalence of HPV associated diseases are the critical factors attributed to the market expansion.

The increase in programs for HPV awareness is one of the effective strategies to increase the vaccination uptake and eliminate HPV-associated cancers. Additionally, in collaboration with computer scientists, HPV-related Epidemiological Research Unit, Norway, developed an innovative approach to communicate the importance of cervical cancer prevention to girls, women, boys, and men of different ages. Therefore, the market in developing countries is likely to show high growth potential over the next few years.

On the contrary, high cost of HPV vaccines hurdles the growth of Europe human papillomavirus (HPV) vaccine market.

Based on type, the Europe human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment held 59.4% market share in 2022, amassing US$ 714.89 million. It is projected to garner US$ 951.43 million by 2028 to expand at 4.9% CAGR during 2022–2028.

Based on dosage, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment held 63.9% market share in 2022, amassing US$ 768.35 million. It is projected to garner US$ 1,009.64 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on age, the Europe human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment held 75.1% market share in 2022, amassing US$ 903.22 million. It is projected to garner US$ 1,191.15 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on application, the Europe human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment held 82.6% market share in 2022, amassing US$ 992.96 million. It is projected to garner US$ 1,334.42 million by 2028 to expand at 5.0% CAGR during 2022–2028.

Based on end user, the Europe human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment held 39.1% market share in 2022, amassing US$ 469.64 million. It is projected to garner US$ 619.06 million by 2028 to expand at 4.7% CAGR during 2022–2028.

Based on country, the Europe human papillomavirus (HPV) vaccine market has been categorized into the U.K., Germany, France, Italy, Spain, Russia, Belarus, and rest of Europe. Our regional analysis states that Germany captured 29.8% market share in 2022. It was assessed at US$ 358.51 million in 2022 and is likely to hit US$ 468.93 million by 2028, exhibiting a CAGR of 4.6% during the forecast period.

Key players dominating the Europe human papillomavirus (HPV) vaccine market are 2A Pharma; ChengDu Institute of Biological Products Co., Ltd.; GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; Vaccitech; and Walvax Biotechnology Co., Ltd. among others.

• In Nov 2021, Merck announced the successful completion of the acquisition of Acceleron Pharma Inc.

• In Feb 2021, QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Human Papillomavirus (HPV) Vaccines Market – By Type

1.3.2 Europe Human Papillomavirus (HPV) Vaccines Market – By Dosage

1.3.3 Europe Human Papillomavirus (HPV) Vaccines Market – By Age

1.3.4 Europe Human Papillomavirus (HPV) Vaccines Market – By Application

1.3.5 Europe Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel

1.3.6 Europe Human Papillomavirus (HPV) Vaccines Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Human Papillomavirus (HPV) Vaccine Market – Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Experts Opinion

5. Europe Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increase in Prevalence of HPV Associated Diseases

5.1.2 Initiatives Taken by Health Organizations

5.2 Market Restraints

5.2.1 High Cost of HPV Vaccines

5.3 Market Opportunities

5.3.1 Growing Number of HPV Awareness Programs

5.4 Future Trends

5.4.1 Advancements in HPV Diagnostics Tests

5.5 Impact Analysis

6. Human Papillomavirus (HPV) Vaccine Market– Europe Analysis

6.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis

7. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – By Type

7.1 Overview

7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)

7.3 9-valent HPV vaccine

7.3.1 Overview

7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.4 Quadrivalent HPV vaccine

7.4.1 Overview

7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.5 Bivalent HPV Vaccine

7.5.1 Overview

7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

8. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage

8.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

8.2 2 Dose

8.2.1 Overview

8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

8.3 3 Dose

8.3.1 Overview

8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Age

9.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

9.2 9 to 14 Years

9.2.1 Overview

9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9.3 to 45 Years

9.3.1 Overview

9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Human Papillomavirus (HPV) Vaccine Market Analysis - By Application

10.1 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

10.2 HPV-attributable Cancer

10.2.1 Overview

10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10.3 Genital Warts

10.3.1 Overview

10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11. Europe Human Papillomavirus (HPV) Vaccine Market Analysis – By End User

11.1 Overview

11.2 Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

11.3 Doctor Office

11.3.1 Overview

11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

11.4 Community Health Clinics

11.4.1 Overview

11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

11.5 School-based Health Centers

11.5.1 Overview

11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

11.6 Health Departments

11.6.1 Overview

11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)

11.7 Hospitals

11.7.1 Overview

11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)

11.8 Others

11.8.1 Overview

11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)

12. Europe Human Papillomavirus (HPV) Vaccine Market - Country Analysis

12.1 Overview

12.1.1 Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.1.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.1 Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.2 Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.3 Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.4 Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.5 Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.6 Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.1 France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.2 France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.3 France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.4 France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.5 France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.6 France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.1 UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.2 UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.3 UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.4 UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.5 UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.6 UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.1 Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.2 Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.3 Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.4 Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.5 Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.6 Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.1 Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.2 Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.3 Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.4 Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.5 Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.6 Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.1 Russia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.2 Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.3 Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.4 Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.5 Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.6 Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.1 Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.2 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.3 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.4 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.5 Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.6 Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.1 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.2 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.3 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.4 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.5 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.6 Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

13. Industry Landscape

13.1 Overview

13.2 Inorganic Growth Strategies

13.2.1 Overview

13.3 Organic Growth Strategies

13.3.1 Overview

14. Company Profiles

14.1 Merck & Co., Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Serum Institute of India Pvt. Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 Walvax Biotechnology Co., Ltd.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Inovio Pharmaceuticals

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Vaccitech

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 2A Pharma

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

14.8 ChengDu Institute of Biological Products Co., Ltd.

14.8.1 Key Facts

14.8.2 Business Description

14.8.3 Products and Services

14.8.4 Financial Overview

14.8.5 SWOT Analysis

14.8.6 Key Developments

14.9 Sanofi

14.9.1 Key Facts

14.9.2 Business Description

14.9.3 Products and Services

14.9.4 Financial Overview

14.9.5 SWOT Analysis

14.9.6 Key Developments

14.10 R-Pharm

14.10.1 Key Facts

14.10.2 Business Description

14.10.3 Products and Services

14.10.4 Financial Overview

14.10.5 SWOT Analysis

14.10.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1.             Europe Human Papillomavirus (HPV) Vaccine Market, Revenue and Forecast, 2019–2028 (US$ Mn)

Table 2.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 4.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 5.             Germany: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 6.             Germany: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             France: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 8.             France: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 9.             France: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 10.          France: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 11.          France: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12.          UK: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 13.          UK: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 14.          UK: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 15.          UK: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 16.          UK: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 19.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 20.          Italy: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Italy: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 23.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 24.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 25.          Spain: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 26.          Spain: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 27.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 28.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 29.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 30.          Russia: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 31.          Russia: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 32.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 33.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 34.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 35.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 36.          Belarus: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 37.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 38.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 39.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 40.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 41.          Rest of Europe: Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 42.          Recent Inorganic Growth Strategies

Table 43.          Recent Organic Growth Strategies

Table 44.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           Europe Human Papillomavirus (HPV) Vaccines Market Segmentation

Figure 2.           Europe Human Papillomavirus (HPV) Vaccines Market, By Country

Figure 3.           Europe Human Papillomavirus (HPV) Vaccine Market Overview

Figure 4.           Europe Human Papillomavirus (HPV) Vaccines Market, By Type

Figure 5.           Europe Human Papillomavirus (HPV) Vaccines Market, By Country

Figure 6.           Europe: PEST Analysis

Figure 7.           Experts Opinion

Figure 8.           Europe Human Papillomavirus (HPV) Vaccines Market Impact Analysis of Driver and Restraints

Figure 9.           Europe Human Papillomavirus (HPV) Vaccine Market– Revenue Forecast and Analysis

Figure 10.        By Type: Market Analysis and Forecast 2022 and 2028 (%)

Figure 11.        Europe 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 12.        Europe Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 13.        Europe Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

Figure 15.        Europe 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        Europe 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

Figure 18.        Europe 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        Europe 15 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 20.        Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

Figure 21.        Europe HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        Europe Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        Europe Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

Figure 24.        Europe Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Europe Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

Figure 26.        Europe School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

Figure 27.        Europe Health Departments Market Revenue and Forecast to 2028 (US$ Million)

Figure 28.        Europe Hospitals Market Revenue and Forecast to 2028 (US$ Million)

Figure 29.        Europe Others Market Revenue and Forecast to 2028 (US$ Million)

Figure 30.        Europe: Human Papillomavirus (HPV) Vaccine Market, by Key Country – Revenue (2022) (US$ Million)

Figure 31.        Europe: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

Figure 32.        Germany: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.        France: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        UK: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 35.        Italy: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 36.        Spain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 37.        Russia Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 38.        Belarus: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

Figure 39.        Rest of Europe: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

The List of Companies - Europe Human Papillomavirus (HPV) Vaccine Market

● 2A Pharma

● ChengDu Institute of Biological Products Co., Ltd.

● GlaxoSmithKline plc.

● Inovio Pharmaceuticals

● Merck & Co., Inc. 

● R-Pharm

● Sanofi

● Serum Institute of India Pvt. Ltd

● Vaccitech  

● Walvax Biotechnology Co., Ltd.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe human papillomavirus (HPV) vaccine market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Europe human papillomavirus (HPV) vaccine market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the human papillomavirus (HPV) vaccine market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

TOP